Clinical Trials Sponsored by AGO Study Group

Total 672 results

AGO Study Group

Completed

Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

Germany
AGO Study Group

Completed

A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

Ovarian Cancer | Peritoneal Cancer | Cancer of the Fallopian Tube

Germany
AGO Study Group

Completed

Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer

Ovarian Cancer
AGO Study Group

Completed

Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Cancer

Germany
AGO Study Group

Completed

Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

Sarcoma | Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer

Germany
AGO Study Group

Completed

Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Cancer

Germany
AGO Study Group

Terminated

Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum

Anemia | Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum | Platinum Sensitve Relapse

Germany
AGO Study Group

Active, not recruiting

Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST)

Ovarian Cancer

United States, France, Germany, Austria, Sweden, Denmark, Italy, United Kingdom
AGO Study Group

Completed

Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma

Ovarian Diseases | Ovarian Neoplasms | Endometrial Neoplasms | Genital Diseases, Female

Germany
AGO Study Group

Completed

Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer

Ovarian Cancer | Fallopian Tube Cancer

Germany
AGO Study Group

Completed

Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer

Epithelial Ovarian Cancer

Germany
AGO Study Group

Completed

Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer

Ovarian Cancer

Germany
German Breast Group
AGO Study Group

Completed

Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)

Breast Cancer

Germany
German Breast Group
AGO Study Group

Completed

Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (GeparQuinto)

Breast Cancer

Germany
AEterna Zentaris
AGO Study Group

Completed

Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors

Ovarian Cancer | Endometrial Cancer

Bulgaria, Germany
West German Study Group
AGO Germany

Completed

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

Breast Cancer

Germany
AGO Study Group
Merck Sharp & Dohme LLC

Completed

Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors

Carcinosarcoma | Leiomyosarcoma | Mesenchymal Tumor

Germany
AGO Study Group

Completed

Epoetin Beta in Treating Anemia in Patients With Cervical Cancer

Cervical Cancer | Anemia

Germany
AGO Study Group
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Recruiting

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

Germany
AGO Study Group
Arbeitsgemeinschaft Gynaekologische Onkologie Austria; MITO

Completed

Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer

Ovarian Cancer

Germany, Belgium, Italy, Austria
German Breast Group
Pfizer; AGO Study Group; Breast International Group; NSABP Foundation Inc

Completed

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery (PENELOPE-B)

Breast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG Score

United States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom
AGO Study Group
Essex Pharma GmbH; MedServ. GmbH, Wiesbaden

Completed

Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours

Cervical Cancers | Cancer of the Ovary Treated as 2nd Line Therapy | Muellerian Mixed Tumours | Tumours of the Uterus | Non-Epithelial Ovarian Tumours

Germany
EEPiDuDa Study Group

Not yet recruiting

EEP in Patients With Urodynamically Proven DU/DA

Lower Urinary Tract Symptoms | Prostatic Hyperplasia | Lower Urinary Tract Obstructive Syndrome | Detrusor Underactivity | Detrusor Areflexia
Ataxia Study Group

Recruiting

The EUROSCA Natural History Study (EUROSCA-NHS)

Spinocerebellar Ataxia

Austria, Belgium, France, Germany, Hungary, Italy, Netherlands, Poland, Spain, United Kingdom
Huntington Study Group

Completed

Making HD Voices Heard

Huntington Disease

United States
Huntington Study Group

Completed

Development of the Virtual Unified Huntington's Disease Rating Scale (vUHDRS)

Huntington Disease

United States
Famirea Study Group

Terminated

A Communication Strategy for Families of Patients Dying in the ICU

Family of Dying Patient in the ICU
ALDUS Study Group

Enrolling by invitation

Surveillance Study for HCC by Combining Biomarkers With Imaging (ALDUS) (ALDUS)

Liver Cirrhosis

Japan
Bistro Study Group

Completed

Quality of Chest Compressions After a Night Shift (WeCAN)

Cardiac Arrest

France
NORDynamIC Study Group

Completed

Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3

Hepatitis C Virus

Sweden
Danish Study Group

Not yet recruiting

Coronary Artery Bypass Grafts or Percutaneous Coronary Intervention for High Risk Patients

LV Dysfunction | IHD

Denmark
SURPRISE Study Group

Completed

Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation (SURPRISE)

Rheumatoid Arthritis

Japan
Tokyo Study Group

Completed

Intervention to Preserve Beta-Cell Function in GAD Ab-Positive Diabetes

GAD Ab Positive Clinically Type 2 Diabetic Patients

Japan
Institut fuer Frauengesundheit
Novartis Pharmaceuticals; AGO Breast Study Group e.V.

Recruiting

Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients (CAPTOR-BC)

Breast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer

Germany
AGO Study Group
Philipps University Marburg Medical Center; medac GmbH

Completed

Chemo- and Radiotherapy in Epithelial Vulvar Cancer (CARE)

Radio/Chemotherapy in Node Positive Advanced Vulvar Cancer

Germany
Institut fuer Frauengesundheit
Novartis Pharmaceuticals; AGO Breast Study Group e.V.

Recruiting

CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer (CLEAR-B)

Breast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer

Germany
West German Study Group
Roche Pharma AG

Active, not recruiting

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. (ADAPT; T-DM1)

Breast Cancer

Germany
West German Study Group
Roche Pharma AG

Recruiting

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol (ADAPT)

Breast Cancer

Germany
Korean Cancer Study Group

Not yet recruiting

Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer
German CLL Study Group

Active, not recruiting

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG)

Chronic Lymphoid Leukemia

Germany
German CLL Study Group

Active, not recruiting

Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL (CLL-Frail)

Chronic Lymphoid Leukemia

Austria, Germany
German CLL Study Group

Completed

Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL (CLL2-BAAG)

Chronic Lymphoid Leukemia

Germany
Korean Cancer Study Group

Withdrawn

A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)

Colorectal Cancer Metastatic
Amgen
TIMI Study Group

Completed

LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy (LAPLACE)

Hyperlipidemia

United States, Canada, Denmark, Czechia, Hungary
Pfizer
TIMI Study Group

Completed

A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)

Dyslipidemias | Hyperlipidemias | Hyperlipoproteinemias

United States, Canada, Poland
Korean Cancer Study Group

Unknown

A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers

Metastatic Solid Tumor | DDR Gene Mutation

Korea, Republic of
Korean Cancer Study Group

Unknown

Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer

Metastatic Breast Cancer | HER2-positive Breast Cancer

Korea, Republic of
Korean Cancer Study Group

Completed

Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer

Hormone Refractory Prostate Cancer

Korea, Republic of
Czech CLL Study Group

Completed

Observational Study in CLL Patients Receiving BR

Chronic Lymphocytic Leukemia

Czechia
German CLL Study Group

Completed

Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany

3

Subscribe